## **OPTIMA HEALTH PLAN**

## PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

<u>Directions:</u> The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; <u>fax to 1-800-750-9692</u>. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. <u>If information provided is not complete, correct, or legible, authorization may be delayed.</u>

□ D	Demser® (metyrosine)	□ <b>Dibenzyline</b> (phenoxybenzamine)	
DRU	UG INFORMATION: Authoriza	ation may be delayed if incomplete.	
Drug	Strength:		
Dosing Schedule:		Length of Therapy:	
Diagn	osis:	ICD Code, if applicable:	
each ?		ow all that apply. All criteria must be met for approval. To support ding lab results, diagnostics, and/or chart notes, must be provided or	
	Diagnosis of pheochromocytoma		
	AND		
	Trial and failure of a selective alpha-	blocker (doxazosin, prazosin, terazosin)	
	<u>AND</u>		
	Trial and failure phenoxybenzamine		
	AND		
		is planned or resection of the tumor is contraindicated or has been ed surgery or contraindication is required)	
	<u>AND</u>		
	If requesting brand Demser®, trial an	d failure of generic metyrosine is required	
	(Continued on next page	ge: signature page is required to process request.)	

## (Please ensure signature page is attached to form.)

## Not all drugs may be covered under every Plan

If a drug is non-formulary on a Plan, documentation of medical necessity will be required.

\*\*Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.\*\*

\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes.\*

Patient Name:	
Member Optima #:	
Prescriber Name:	
Prescriber Signature:	Date:
Office Contact Name:	
Phone Number:	Fax Number:
DEA OR NPI #:	

REVISED/UPDATED: 11/5/2020

<sup>\*</sup>Approved by Pharmacy and Therapeutics Committee: 7/16/2020